<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02782663</url>
  </required_header>
  <id_info>
    <org_study_id>M14-327</org_study_id>
    <secondary_id>2015-003759-23</secondary_id>
    <nct_id>NCT02782663</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants With Crohn's Disease</brief_title>
  <official_title>A Phase 2, Multicenter, Open-Label Extension (OLE) Study to Observe the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Subjects With Crohn's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a open-label extension (OLE) study designed to evaluate the long-term efficacy,
      safety, and tolerability of Upadacitinib (ABT-494).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 18, 2016</start_date>
  <completion_date type="Anticipated">September 17, 2025</completion_date>
  <primary_completion_date type="Anticipated">September 17, 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Achieving Remission</measure>
    <time_frame>Up to Month 96</time_frame>
    <description>It is defined as the percentage of participants achieving clinical remission and endoscopic remission.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants in Remission at Week 0 Who Maintain Remission</measure>
    <time_frame>Up to Month 96</time_frame>
    <description>Remission is defined as participants achieving clinical remission and endoscopic remission.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Achieving Response</measure>
    <time_frame>Up to Month 96</time_frame>
    <description>It is defined as the percentage of participants achieving clinical response and endoscopic response.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Achieving Clinical Remission</measure>
    <time_frame>Up to Month 96</time_frame>
    <description>Clinical remission is defined based on the patient reported outcomes: average daily stool frequency and average daily abdominal pain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Achieving Modified Clinical Remission</measure>
    <time_frame>Up to Month 96</time_frame>
    <description>Clinical remission is defined as change from baseline in the patient reported outcomes: average daily stool frequency and average daily abdominal pain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Achieving Enhanced Clinical Response</measure>
    <time_frame>Up to Month 96</time_frame>
    <description>Enhanced clinical response is defined as change from baseline in the patient reported outcomes: average daily stool frequency and average daily abdominal pain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Achieving Clinical Response</measure>
    <time_frame>Up to Month 96</time_frame>
    <description>Clinical response is defined as change from baseline in the patient reported outcomes: average daily stool frequency and average daily abdominal pain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Achieving Endoscopic Remission</measure>
    <time_frame>Up to Month 96</time_frame>
    <description>Endoscopic remission is based on Simplified Endoscopic Score for Crohn's disease.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants in Endoscopic Remission at Week 0 Who Maintain Endoscopic Remission</measure>
    <time_frame>Up to Month 96</time_frame>
    <description>Endoscopic remission is based on Simplified Endoscopic Score for Crohn's disease.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Achieving Endoscopic Improvement</measure>
    <time_frame>Up to Month 96</time_frame>
    <description>Endoscopic improvement is based on changes from baseline on the Simplified Endoscopic Score for Crohn's disease or endoscopic remission.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Achieving Endoscopic Response</measure>
    <time_frame>Up to Month 96</time_frame>
    <description>Endoscopic response is based on changes from baseline on the Simplified Endoscopic Score for Crohn's disease.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Achieving Crohn's Disease Activity Index (CDAI) Remission</measure>
    <time_frame>Up to Month 96</time_frame>
    <description>It is defined as CDAI less than 150.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Achieving Crohn's Disease Activity Index (CDAI) Response</measure>
    <time_frame>Up to Month 96</time_frame>
    <description>CDAI response is defined as a reduction in CDAI by &gt;= 70 from baseline of Study M13-740.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Achieving Enhanced CDAI Response</measure>
    <time_frame>Up to Month 96</time_frame>
    <description>Enhanced CDAI response is defined as reduction in CDAI by &gt;= 100 from baseline of Study M13-740.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Achieving Inflammatory Bowel Disease Questionnaire (IBDQ) Remission</measure>
    <time_frame>Up to Month 96</time_frame>
    <description>IBDQ remission is defined as IBDQ &gt;= 170.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Achieving IBDQ Response</measure>
    <time_frame>Up to Month 96</time_frame>
    <description>IBDQ response is defined as an increase in IBDQ score &gt;= 16 point from Baseline of Study M13-740.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Taking Steroids at Baseline (of Study M13-740) Who Are Steroid-Free</measure>
    <time_frame>Up to Month 96</time_frame>
    <description>Percentage of participants taking steroids at Baseline (of Study M13-740) who are steroid-free</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Taking Steroids at Baseline (of Study M13-740) Who Are Steroid-Free for At Least 90 Days and Achieve Remission</measure>
    <time_frame>Up to Month 96</time_frame>
    <description>Percentage of participants taking steroids at Baseline (of Study M13-740) who are steroid-free for at least 90 days over time and achieve Remission</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Achieving Remission and Normal C-Reactive Protein</measure>
    <time_frame>Up to Month 96</time_frame>
    <description>Percentage of participants achieving Remission and normal C-reactive protein. Remission is defined as Clinical Remission AND Endoscopic Remission.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">107</enrollment>
  <condition>Crohn's Disease (CD)</condition>
  <arm_group>
    <arm_group_label>Upadacitinib (ABT-494) Dose A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open label dose A once daily (QD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Upadacitinib (ABT-494) Dose B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open label dose B QD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-494</intervention_name>
    <description>Tablet: Oral</description>
    <arm_group_label>Upadacitinib (ABT-494) Dose A</arm_group_label>
    <arm_group_label>Upadacitinib (ABT-494) Dose B</arm_group_label>
    <other_name>Upadacitinib</other_name>
    <other_name>RINVOQ</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant must have completed Study M13-740 through Week 52.

          -  If female, participant must be postmenopausal, surgically sterile or on using a birth
             control method.

        Exclusion Criteria:

          -  For any reason participant is considered by the investigator to be an unsuitable
             candidate

          -  Female participant with a positive pregnancy test at Baseline or who is considering
             becoming pregnant during the study.

          -  Participant is not in compliance with prior and concomitant medication requirements
             and procedures throughout Study M13-740.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ucsd /Id# 150041</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ California, San Francisco /ID# 149987</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143-2204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida - Archer /ID# 150033</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ctr for Gastro Disorders /ID# 150012</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nature Coast Clinical Research /ID# 149975</name>
      <address>
        <city>Inverness</city>
        <state>Florida</state>
        <zip>34452</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastro Assoc of Central GA /ID# 149870</name>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <zip>31201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastrointestinal Specialists /ID# 150015</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cotton-O'Neil Clinical Res Ctr /ID# 149900</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Louisville /ID# 149884</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Clinical Research /ID# 149886</name>
      <address>
        <city>Annapolis</city>
        <state>Maryland</state>
        <zip>21401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charm City Research Group /ID# 150040</name>
      <address>
        <city>Towson</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Digestive Health /ID# 150008</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48098-6363</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - Rochester /ID# 149894</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas City Research Institute /ID# 149888</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University-School of Medicine /ID# 149899</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Langone Long Island CRA /ID# 149976</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia Univ Medical Center /ID# 149895</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032-3725</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ NC Chapel Hill /ID# 149982</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514-4220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati /ID# 149977</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267-0585</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Options Health Research, LLC /ID# 150010</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Digestive Disease Consul /ID# 149869</name>
      <address>
        <city>Southlake</city>
        <state>Texas</state>
        <zip>76092</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Digestive Disease Consul /ID# 149989</name>
      <address>
        <city>Southlake</city>
        <state>Texas</state>
        <zip>76092</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aspen Clinical Research /ID# 150020</name>
      <address>
        <city>Orem</city>
        <state>Utah</state>
        <zip>84058</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JLUniversity of Virginia /ID# 149881</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Mason Medical Center /ID# 150042</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington /ID# 149988</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>WI Center for Advanced Res /ID# 149863</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Liege /ID# 149912</name>
      <address>
        <city>Liège</city>
        <state>Liege</state>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Alberta /ID# 149873</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2W 4X9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ British Columbia /ID# 149876</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GIRI Gastrointestinal Research Institute /ID# 149878</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 2K5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Digestive Disease Asso /ID# 149877</name>
      <address>
        <city>Vaughan</city>
        <state>Ontario</state>
        <zip>L4L 4Y7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill Univ HC /ID# 149871</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3G 1A4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hepato-Gastroenterologie HK s.r.o. /ID# 149882</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>500 12</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aarhus University Hospital /ID# 149919</name>
      <address>
        <city>Aarhus N</city>
        <state>Midtjylland</state>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hvidovre Hospital /ID# 149890</name>
      <address>
        <city>Hvidovre</city>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Lille - Hôpital Claude Huriez /ID# 149897</name>
      <address>
        <city>Lille CEDEX</city>
        <state>Hauts-de-France</state>
        <zip>59045</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU NANCY - Hôpital Brabois Adultes /ID# 149896</name>
      <address>
        <city>Vandoeuvre les Nancy CEDEX</city>
        <state>Meurthe-et-Moselle</state>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Amiens Picardie /ID# 149921</name>
      <address>
        <city>Amiens CEDEX 1</city>
        <state>Somme</state>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ Hosp Schleswig-Holstein /ID# 149936</name>
      <address>
        <city>Kiel</city>
        <state>Schleswig-Holstein</state>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DRK-Kliniken Westend /ID# 149905</name>
      <address>
        <city>Berlin</city>
        <zip>14050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinisches Versorgungszentrum Portal 10 /ID# 149930</name>
      <address>
        <city>Munster</city>
        <zip>48155</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Magyar Elhizastudomanyi KKft. /ID# 149907</name>
      <address>
        <city>Budapest</city>
        <zip>1124</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center /ID# 149942</name>
      <address>
        <city>Petakh Tikva</city>
        <state>Tel-Aviv</state>
        <zip>4941492</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Assaf Harofeh Medical Center /ID# 149943</name>
      <address>
        <city>Be'er Ya'akov</city>
        <zip>70300</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center /ID# 149945</name>
      <address>
        <city>Ramat Gan</city>
        <zip>5262100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita di Catanzaro Magna Graecia /ID# 149927</name>
      <address>
        <city>Catanzaro</city>
        <state>Calabria</state>
        <zip>88100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.U. Policlinico S.Orsola-Malpighi /ID# 149958</name>
      <address>
        <city>Bologna</city>
        <state>Emilia-Romagna</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JLAcademisch Medisch Centrum /ID# 149932</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum Utrecht /ID# 149933</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dunedin Hospital /ID# 149964</name>
      <address>
        <city>Dunedin</city>
        <zip>9016</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lovisenberg Diakonale Sykehus /ID# 149967</name>
      <address>
        <city>Oslo</city>
        <zip>0440</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.M. Szpital Swietej Rodziny /ID# 149979</name>
      <address>
        <city>Lodz</city>
        <state>Lodzkie</state>
        <zip>90-302</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centralny Szpital Kliniczny MSWiA w Warszawie /ID# 149978</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>02-507</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabinet Particular Policlinic Algomed /ID# 149993</name>
      <address>
        <city>Timisoara</city>
        <zip>300002</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KM Management s.r.o, Nitra, SK /ID# 149949</name>
      <address>
        <city>Nitra</city>
        <zip>949 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastro I.S.R.O. /ID# 149948</name>
      <address>
        <city>Presov</city>
        <zip>08001</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Arquitecto Marcide /ID# 149996</name>
      <address>
        <city>Ferrol</city>
        <zip>15405</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz /ID# 149997</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manchester Royal Infirmary, Ma /ID# 150006</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Radcliffe Hospital /ID# 149963</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.rxabbvie.com/</url>
    <description>This clinical study may be evaluating a usage that is not currently FDA approved. Please see US Prescribing Information for approved uses.</description>
  </link>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>May 23, 2016</study_first_submitted>
  <study_first_submitted_qc>May 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2016</study_first_posted>
  <last_update_submitted>February 13, 2020</last_update_submitted>
  <last_update_submitted_qc>February 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Crohn's Disease</keyword>
  <keyword>Efficacy</keyword>
  <keyword>Safety</keyword>
  <keyword>Tolerability</keyword>
  <keyword>ABT-494</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Upadacitinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.</ipd_time_frame>
    <ipd_access_criteria>Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.</ipd_access_criteria>
    <ipd_url>https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

